Across TCGA pan-cancer cohorts, GTF2E2 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated GTF2E2 data layer compared with 3 for mutation status and 4 for mass-spec protein.
The strongest signal is observed in mesothelioma (MESO), where higher GTF2E2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated GTF2E2 expression acts as an unfavorable survival marker, although some lineages such as THCA and CESC show a favorable association.
MESO, KICH, and KIRP are the cancer types where GTF2E2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.